Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Radiation Injuries 2Ovarian Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Brain Neoplasms 2Xerostomia 1Wilms Tumor 1Uterine Cervical Neoplasms 1Testicular Neoplasms 1Teratoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Retinoblastoma 1Ovarian Germ Cell Cancer 1Oropharyngeal Neoplasms 1Neurotoxicity Syndromes 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mucositis 1Mouth Neoplasms 1Medulloblastoma 1Liver Neoplasms 1Laryngeal Neoplasms 1Kidney Neoplasms 1

Interventions

Melphalan 5Filgrastim 4birtamimab 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pomalidomide 2Calcium Dobesilate 2Bortezomib 2venetoclax 1pegfilgrastim 1nelarabine 1melflufen 1daratumumab 1Tetradecanoylphorbol Acetate 1Peripheral Blood Stem Cell Transplantation 1Oxycodone 1Moxifloxacin 1Morphine 1Methadone 1Fluorescent Antibody Technique 1Fentanyl 1Diuretics 1Ciprofloxacin 1Blood Component Removal 1Amoxicillin-Potassium Clavulanate Combination 1Amifostine 14'-deoxy-4'-iododoxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immunoglobulin Light-chain Amyloidosis × Amifostine × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡